Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
May 9, 2017 7:00 AM EDTLAVAL, Quebec, May 9, 2017 /PRNewswire/ --
First Quarter Financial Results Revenues of $2.109 Billion GAAP Net Income of $628 Million GAAP Cash Flow from Operations of $954 Million Adjusted EBITDA (non-GAAP) of $861 Million Adjusted Net Income (non-GAAP) of $273 Million Reduced Debt by $1.3 Billion in the quarter Raising 2017 Full Year Adjusted EBITDA Guidance RangeMay 9, 2017 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)... More
